Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 312

1.

Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates.

Ho J, Jelfs P, Sintchenko V.

Int J Infect Dis. 2014 Sep;26:149-53. doi: 10.1016/j.ijid.2014.03.1388. Epub 2014 Jul 30.

2.

Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes.

Surcouf C, Heng S, Pierre-Audigier C, Cadet-Daniel V, Namouchi A, Murray A, Gicquel B, Guillard B.

BMC Infect Dis. 2011 Sep 28;11:255. doi: 10.1186/1471-2334-11-255.

3.

The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.

Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, Steingart KR, Dheda K.

Cochrane Database Syst Rev. 2014 Oct 29;(10):CD010705. doi: 10.1002/14651858.CD010705.pub2. Review.

4.

Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003.

Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC.

J Antimicrob Chemother. 2005 Dec;56(6):1058-62. Epub 2005 Oct 4.

PMID:
16204341
5.

Correlations between drug resistance of Beijing/W lineage clinical isolates of Mycobacterium tuberculosis and sublineages: a 2009-2013 prospective study in Xinjiang province, China.

Wang XH, Ma AG, Han XX, Gu XM, Fu LP, Li PG, Li FY, Wang QZ, Liang H, Katar A, Wang LJ.

Med Sci Monit. 2015 May 7;21:1313-8. doi: 10.12659/MSM.892951.

6.

Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Takiff H, Guerrero E.

Antimicrob Agents Chemother. 2011 Dec;55(12):5421-9. doi: 10.1128/AAC.00695-11. Epub 2011 Aug 29. Review.

7.

Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: Implications for disease control.

Jabeen K, Shakoor S, Malik F, Hasan R.

Int J Mycobacteriol. 2015 Mar;4 Suppl 1:47-8. doi: 10.1016/j.ijmyco.2014.10.046. Epub 2014 Dec 22.

8.

Evaluation of a line probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis.

Ando H, Mitarai S, Kondo Y, Suetake T, Kato S, Mori T, Kirikae T.

J Med Microbiol. 2011 Feb;60(Pt 2):184-8. doi: 10.1099/jmm.0.024729-0. Epub 2010 Nov 4.

PMID:
21051549
9.

Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.

Jeong BH, Jeon K, Park HY, Kwon OJ, Lee KS, Kim HK, Choi YS, Kim J, Huh HJ, Lee NY, Koh WJ.

J Antimicrob Chemother. 2015 Nov;70(11):3127-33. doi: 10.1093/jac/dkv215. Epub 2015 Jul 22.

PMID:
26203184
10.

Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.

Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC.

J Antimicrob Chemother. 2007 May;59(5):860-5. Epub 2007 Apr 5.

PMID:
17412727
11.

Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China.

Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y.

Antimicrob Agents Chemother. 2014;58(1):364-9. doi: 10.1128/AAC.01228-13. Epub 2013 Oct 28.

12.

Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey.

Umubyeyi AN, Rigouts L, Shamputa IC, Fissette K, Elkrim Y, de Rijk PW, Struelens MJ, Portaels F.

J Antimicrob Chemother. 2007 May;59(5):1031-3. Epub 2007 Feb 28.

PMID:
17329272
13.

Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.

Zhu C, Zhang Y, Shen Y, Siu GK, Wu W, Qian X, Deng G, Xu Y, Lau R, Fan X, Zhang W, Lu H, Yam WC.

Diagn Microbiol Infect Dis. 2012 Jul;73(3):260-3. doi: 10.1016/j.diagmicrobio.2012.03.025. Epub 2012 May 4.

PMID:
22560167
14.

Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates.

Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W.

J Clin Microbiol. 2010 May;48(5):1683-9. doi: 10.1128/JCM.01947-09. Epub 2010 Mar 24.

15.

Resistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: trends over time.

Dalal A, Pawaskar A, Das M, Desai R, Prabhudesai P, Chhajed P, Rajan S, Reddy D, Babu S, Jayalakshmi TK, Saranchuk P, Rodrigues C, Isaakidis P.

PLoS One. 2015 Jan 21;10(1):e0116798. doi: 10.1371/journal.pone.0116798. eCollection 2015.

16.

Fluoroquinolone resistance among Mycobacterium tuberculosis strains from Karachi, Pakistan: data from community-based field clinics.

Rafiq Y, Jabeen K, Hasan R, Jafri S, Laiq R, Malik F, Mangi R, Channa A, Hasan Z.

Antimicrob Agents Chemother. 2011 Feb;55(2):929-30. doi: 10.1128/AAC.00931-10. Epub 2010 Dec 6.

17.

Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.

Mpagama SG, Houpt ER, Stroup S, Kumburu H, Gratz J, Kibiki GS, Heysell SK.

BMC Infect Dis. 2013 Sep 14;13:432. doi: 10.1186/1471-2334-13-432.

18.

Assessment of trends of ofloxacin resistance in Mycobacterium tuberculosis.

Verma JS, Nair D, Rawat D, Manzoor N.

Indian J Med Microbiol. 2011 Jul-Sep;29(3):280-2. doi: 10.4103/0255-0857.83913.

19.

Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.

Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, Paramasivan CN, Narayanan PR, Sahu S, Parmar M, Chadha S, Dewan P, Chauhan LS.

Int J Tuberc Lung Dis. 2009 Sep;13(9):1154-60.

PMID:
19723407
20.

[Investigation of extensive drug resistance in multidrug resistance tuberculosis isolates].

Bektöre B, Haznedaroğlu T, Baylan O, Ozyurt M, Ozkütük N, Satana D, Cavuşoğlu C, Seber E.

Mikrobiyol Bul. 2013 Jan;47(1):59-70. Turkish.

Supplemental Content

Support Center